Renin-Angiotensin Aldosterone System and Fibrinolysis(RAAS) Interaction in Humans- Specific Aim 3
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Net Tissue-type Plasminogen Activator (t-PA) Release
研究概览
简要总结
The purpose of the study is to determine if giving isosorbide,a drug that is used to treat chest pain, affects blood vessel release of an anti-clotting factor.
详细描述
To test the hypothesis that the administration of the NO donor isosorbide dinitrate,but not the phosphodiesterase inhibitor sildenafil, will attenuate stimulated vascular t-PA release whereas both agents will improve glucose uptake.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Health Services Research
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •18-70 years of age
- •Male and female subjects
- •Surgical sterilization
- •Childbearing potential: beta HCG on study day
- •Subjects with a body mass index of 25 or greater
排除标准
- •Diabetes type 1 to type 2 as defined by a fasting glucose of 126 mg/dl or greater or the use of anti-diabetic medication
- •Use of hormone replacement therapy
- •Statin therapy
- •In hypertensive subjects, a seated systolic blood pressure greater than 179 mmHg or a seated diastolic blood pressure greater than 110 mmHg or taking hypertensives
- •Pregnancy/Breast Feeding
- •Cardiovascular disease such as myocardial infarction with 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable) deep vein thrombosis, pulmonary embolism, second or three degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy
- •Treatment with anticoagulants
- •History of serious neurologic disease such as cerebral hemorrhage, stroke or transient ischemic attack
- •Diagnosis of asthma
- •Clinically significant gastrointestinal impairment that could interfere with drug absorption
- •Hematocrit <35%
- •Hyperlipidemic fasting Total Cholesterol >220mg/dl
- •Impaired renal function (Serum creatinine >1.5 mg/dl)
- •History or presence of immunological or hematological disorders
- •Any underlying or acute disease requiring regular medication which could possible pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult
- •Impaired hepatic function (Serum glutamic oxaloacetic transaminase, serum glutamate pyruvate transaminase > 60)
- •Treatment with chronic systemic glucocorticoid therapy (more than 7 days in 1 month)
- •Treatment with lithium salts
- •History of Alcohol or drug abuse
- •Treatment with any investigational drug 1 month preceding study
- •Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study
- •Inability to comply with the protocol
研究组 & 干预措施
Control (bradykinin infusion)
Bradykinin (Clinalfa AG, Läufelfingen, Switzerland)
干预措施: Control (bradykinin) (Drug)
L-NMMA + bradykinin
N-monomethyl-L-arginine (L-NMMA, NO synthase inhibitor; Bachem, Torrance, CA)
干预措施: L-NMMA + bradykinin (Drug)
Isosorbide + L-NMMA + bradykinin
Isosorbide (NO donor)
干预措施: Isosorbide + L-NMMA + bradykinin (Drug)
Sildenafil + L-NMMA + bradykinin
Sildenafil (phosphodiesterase type 5 (PDE5) inhibitor
干预措施: Sildenafil + L-NMMA + bradykinin (Drug)
结局指标
主要结局
Net Tissue-type Plasminogen Activator (t-PA) Release
时间窗: During and after each study drug administration
Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x \[101-hematocrit/100\]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively.
次要结局
- Forearm Blood Flow (FBF)(During and after each study drug administration)
研究者
Nancy J. Brown
Professor of Medicine and Clinical Pharmacology
Vanderbilt University